Skip to main content
. 2020 Nov 3;5:20. doi: 10.1038/s41536-020-00106-y

Fig. 1. Roadmap of clinical considerations regarding the use of MSCs in PD therapy.

Fig. 1

Relevant sources of variability in clinical trials for PD include patient factors, MSC sources, dose delivery, and clinical outcomes of therapy. Created using elements of Servier Medical Art by Servier, licensed under CC BY 3.0 (https://smart.servier.com/).